Tumour Markers in Prostatic Carcinoma. A Comparison of Prostate‐specific Antigen with Acid Phosphatase

Wiley - Tập 60 Số 1 - Trang 69-73 - 1987
M. Ferro1,2, I Barnes1,3, Julian Roberts1,4, Patrick J. Smith1,5
1Departments of Urology and Biochemistry, Royal Infirmary, Bristol
2M. A. Ferro, FRCS, Research Fellow and Tutor in Urology.
3I. Barnes, PhD, Principal Biochemist.
4J. B. M. Roberts, ChM, FRCS, Consultant Urologist.
5P. J. B. Smith, ChM, FRCS, Consultant Urologist.

Tóm tắt

Summary— A study was performed on 130 men to compare the level of serum prostate‐specific antigen (PSA) in controls, patients with benign prostatic hyperplasia (BPH) and patients with prostatic carcinoma. The results showed that all 30 normal controls below 40 years of age had values less than 10 ng/ml. Of the 40 patients with BPH, all aged over 40 years, 13 (32.5%) had raised levels above 10 ng/ml. In the 60 patients with prostatic carcinoma, all over 40 years, 24 had localised disease (M0) and 36 had metastatic spread (M1), as judged by isotope bone scan. In patients with M0 disease, 16 (66.6%) had raised PSA levels compared with 34 (94.5%) of those with M1 disease. The corresponding figures for raised prostatic acid phosphatase (PAP) values were 4% in the M0 group and 52.7% in the M1 group.PSA levels reflected neither the histological grade nor the local stage of the tumour and were of no value in estimating tumour burden.PSA was found to be a valuable index in the management of prostatic cancer because of this sensitivity. Stable disease not requiring hormonal manipulation was reflected by unchanging levels of PSA, whereas progressive disease requiring hormonal therapy was reflected by an alteration in the PSA levels corresponding to the patients' response. The same group of progressive disease patients showed only a 50% rise in serum PAP levels, confirming the greater sensitivity of PSA as a measure of prostate cancer. PSA measurements should be included in any further trials on prostatic carcinoma and should be regarded as a standard marker for evaluating response to therapy.

Từ khóa


Tài liệu tham khảo

Amador E., 1969, Serum a‐L naphthol phosphatase activity, Am. J. Clin. Pathol., 51, 202, 10.1093/ajcp/51.2.202

Frankel A. E., 1982, Monoclonal antibodies to a human prostate antigen, Cancer Res., 42, 3714

Killian C. S., 1985, Prognostic importance of prostatic‐specific antigen for monitoring patients with stages B2 to D1 prostate cancer, Cancer Res., 45, 886

Kuriyama M., 1982, Multiple marker evaluation in human prostate cancer with the use of tissue specific antigens, J. Natl. Cancer Inst., 68, 99

Kuriyama M., 1980, Quantitation of prostate‐specific antigen in serum by a sensitive enzyme immunoassay, Cancer Res., 40, 4568

Liedtke R. J., 1984, Measurement of prostate‐specific antigen by radioimmunoassay, Clin. Chem., 30, 649, 10.1093/clinchem/30.5.649

10.1002/1097-0142(19810901)48:5<1229::AID-CNCR2820480529>3.0.CO;2-L

Papsidero L. D., 1980, A prostate antigen in the sera of prostatic cancer patients, Cancer Res., 40, 2428

10.1016/S0022-5347(17)51675-4

Wang M. C., 1979, Purification of a human prostate—specific antigen, Invest. Urol., 17, 159

10.1016/S0022-5347(17)47311-3

Thông tin
Thông tin xuất bản

Wiley

Tập 60 Số 1

69-73

Thông tin tác giả